These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 33008584)
1. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis. Wang L; Chen Y; Mi Y; Qiao J; Jin H; Li J; Lu Z; Wang Q; Zou Z Biochem Biophys Res Commun; 2021 Jun; 558():216-223. PubMed ID: 33008584 [TBL] [Abstract][Full Text] [Related]
2. NR5A2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis. Qiao J; Chen Y; Mi Y; Jin H; Huang T; Liu L; Gong L; Wang L; Wang Q; Zou Z Biochem Biophys Res Commun; 2020 Sep; 530(2):402-409. PubMed ID: 32536370 [TBL] [Abstract][Full Text] [Related]
3. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665 [TBL] [Abstract][Full Text] [Related]
4. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532 [TBL] [Abstract][Full Text] [Related]
5. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544 [TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878 [TBL] [Abstract][Full Text] [Related]
7. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Roh JL; Kim EH; Jang H; Shin D Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440 [TBL] [Abstract][Full Text] [Related]
8. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Shin D; Kim EH; Lee J; Roh JL Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884 [TBL] [Abstract][Full Text] [Related]
9. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872 [TBL] [Abstract][Full Text] [Related]
10. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909 [TBL] [Abstract][Full Text] [Related]
12. Regulation of GSK3β/Nrf2 signaling pathway modulated erastin-induced ferroptosis in breast cancer. Wu X; Liu C; Li Z; Gai C; Ding D; Chen W; Hao F; Li W Mol Cell Biochem; 2020 Oct; 473(1-2):217-228. PubMed ID: 32642794 [TBL] [Abstract][Full Text] [Related]
13. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer. Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644 [TBL] [Abstract][Full Text] [Related]
15. Vitamin C Sensitizes Melanoma to BET Inhibitors. Mustafi S; Camarena V; Volmar CH; Huff TC; Sant DW; Brothers SP; Liu ZJ; Wahlestedt C; Wang G Cancer Res; 2018 Jan; 78(2):572-583. PubMed ID: 29180474 [TBL] [Abstract][Full Text] [Related]
16. BET Inhibitors Potentiate Chemotherapy and Killing of Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532 [TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related]
19. 6'-O-galloylpaeoniflorin regulates proliferation and metastasis of non-small cell lung cancer through AMPK/miR-299-5p/ATF2 axis. Gao J; Song L; Xia H; Peng L; Wen Z Respir Res; 2020 Feb; 21(1):39. PubMed ID: 32014006 [TBL] [Abstract][Full Text] [Related]
20. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]